RI
KLRS

RTW Investments’s Kalaris Therapeutics KLRS Stock Holding History

RTW Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.5M Hold
1,300,000
– – 0.07% 74
2025
Q4 		$11M Buy
+1,300,000
New +$8.31M 0.11% 71

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RTW Investments's KLRS Position: Q1 2026 in Review

RTW Investments held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 1,300,000 shares worth $7.5M. The position accounts for 0.07% of the portfolio, ranked #74.

RTW Investments first reported a position in KLRS in Q4 2025 and has held it in 2 quarters since. The position peaked at $11M in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • RTW Investments held 1,300,000 shares of Kalaris Therapeutics worth $7.5M as of Q1 2026.
  • RTW Investments left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up 0.07% of RTW Investments's portfolio in Q1 2026, its #74 holding.
  • RTW Investments first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • RTW Investments's Kalaris Therapeutics position peaked at $11M in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.